COMMONWEALTH OF MASSACHUSETTS

SUFFOLK COUNTY	BOARD OF REGISTRATION	
	IN PHARMACY	Received
In the Matter of John N. Okowitz, R.Ph. Pharmacist Registration No. 17087)	Docket No. PH-07-101	AUG 02 2007
		BOARD OF

CONSENT AGREEMENT

The Board of Registration in Pharmacy ("Board") and John N. Okowitz, R.Ph. ("Registrant"), a pharmacist registered by the Board (Pharmacist Registration No. 17087), do hereby stipulate and agree that the following information shall be entered into and become a permanent part of the file of the Registrant which is maintained by the Board:

- 1. The parties enter into this Consent Agreement ("Agreement") in order to resolve that certain complaint pending against the Registrant as Docket No. PH-07-101 (the "Complaint").
- 2. The Complaint alleged that on or about January 10, 2007, while employed as a pharmacist at Soldiers Home, 100 Cherry Street, Holyoke, Massachusetts, Registrant dispensed Oramorph SR 100mg rather than Methylin 20 mg as authorized.
- 3. Accordingly, the Registrant freely agrees to the following:
 - a. That the conduct described in Paragraph 2 above constitutes professional misconduct which warrants disciplinary action pursuant to G.L. c. 112, §§ 42A and 61 and 247 CMR 9.01(1); and
 - Registrant's Massachusetts Pharmacist Registration is hereby REPRIMANDED by the Board for Registrant's conduct in this matter;
 - c. Registrant shall complete two (2) hours of continuing education (CE) related to medication error prevention topics and submit the ORIGINAL CE certificates of completion to the Board along with a copy of the Agreement within ninety (90) days of the Effective date of the Agreement; and
 - d. Registrant shall file a USP Medication Error Report (USP Report) with USP Practitioners Reporting Network and submit a copy of the report to the Board along with a copy of the Agreement within ninety (90) days of the Effective date of the Agreement; and
 - e. The Registrant shall return a signed copy of this Agreement to the Board within ten (10) days of receipt.

- The Agreement and its contents shall become a part of the records maintained by the Board, and as such, is a public record subject to disclosure to the public, other licensing boards, and the National Association of Boards of Pharmacy.
- The Board agrees that in return for the Registrant's execution of this Agreement, and compliance with the terms and conditions outlined in Paragraph 3, the Board will not advance the prosecution of the Registrant pursuant to the Complaint; any and all other rights of the Board to take action within the scope of its authority are expressly reserved.
- The Registrant understands and agrees that his failure to abide by the terms of this Agreement shall nullify the representations contained in Paragraph 5 and permit the Board to initiate formal adjudicatory action under the State Administrative Procedure Act (G.L. c. 30A) and 801 CMR 1.00 et. seg.
- 7. The Registrant understands and agrees that his decision to enter into this Agreement and to accept the terms and conditions herein described is a final act and is not subject to reconsideration or judicial review.
- 8. The Registrant states that he has used legal counsel in connection with his decision to enter into this Agreement or, if he did not, that he had an opportunity to do so and that his decision to enter into this Agreement was made of his own free will.
- 9. Registrant certifies that he has read this document entitled "Consent Agreement." The Registrant understands that, by executing this Agreement, he is waiving his right to a formal hearing at which time he would possess the rights to confront and cross-examine witnesses, to call witnesses, to present evidence, to testify on his own behalf, to contest the allegations, to present oral argument, to appeal to the court in the event of an adverse ruling, and all other rights set forth in the State Administrative Procedure Act, G.L. c. 30A, and the Standard Adjudicatory Rules of Practice and Procedure, 801 CMR 1.01 et seq.

Witness (print name)

Jøhn N. Okowitz, R.Ph.

Registrant

2-20-03 Date:

James T. DeVita, R.Ph.

Effective Date: 8/2/2007

Dec. No.1605